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BACKGROUND: Current guidelines advise providers to
assess smokers’ readiness to quit, then offer cessation
therapies to smokers planning to quit and motivational
interventions to smokers not planning to quit.
OBJECTIVES: We examined the relationship between
baseline stage of change (SOC), treatment utilization,
and smoking cessation to determine whether the effect
of a proactive smoking cessation intervention was depen-
dent on smokers’ level of motivation to quit.
DESIGN:Secondary analysis of amulticenter randomized
controlled trial.
PARTICIPANTS: A total of 3006 current smokers, aged
18–80 years, at four Veterans Affairs (VA) medical centers.
Interventions: Proactive care included proactive outreach
(mailed invitation followed by telephone outreach), offer of
smoking cessation services (telephone or face-to-face),
and access to pharmacotherapy. Usual care participants
had access to VA smoking cessation services and state
telephone quitlines.
MAIN MEASURES: Baseline SOC measured with Readi-
ness to Quit Ladder, and 6-month prolonged abstinence
self-reported at 1 year.
KEY RESULTS: At baseline, 35.8 % of smokers were in
preparation, 38.2 % in contemplation, and 26.0 % in
precontemplation. The overall interaction between SOC
and treatment arm was not statistically significant
(p=0.30). Among smokers in preparation, 21.1 % of pro-
active care participants achieved 6-month prolonged ab-
stinence, compared to 13.1 % of usual care participants
(OR, 1.8 [95 % CI, 1.2–2.6]). Similarly, proactive care in-
creased abstinence among smokers in contemplation
(11.0 % vs. 6.5 %; OR, 1.8 [95 % CI, 1.1–2.8]). Smokers
in precontemplation quit smoking at similar rates (5.3 %
vs. 5.6 %; OR, 0.9 [95 % CI, 0.5–1.9]). Within each stage,
uptake of smoking cessation treatments increased with
higher SOC and with proactive care as compared with
usual care.
LIMITATIONS:Mostly male participants limits generaliz-
ability. Randomization was not stratified by SOC.
CONCLUSIONS: Proactive care increased treatment up-
take compared to usual care across all SOC. Proactive
care increased smoking cessation among smokers in
pr epara t i on and con temp l a t i on but no t in
precontemplation. Proactively offering cessation thera-
pies to smokers at all SOC will increase treatment utiliza-
tion and population-level smoking cessation.
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INTRODUCTION
Current US smokers overwhelmingly want to quit (68.8 %),
andmost make at least one quit attempt each year (52.4%), yet
they rarely achieve sustained abstinence (6.2 % per year).1 As
a result, the prevalence of smoking in the US has plateaued at
approximately 18 % of adults.2 Evidence-based smoking ces-
sation therapies such as medication and counseling signifi-
cantly increase the success of quit attempts,3,4 but these
therapies are underutilized.1,5 Current models of care for
tobacco cessation treatment rely on highly motivated
smokers to initiate therapy (e.g., by calling state telephone
quitlines) or on clinical providers to offer therapy. The US
Clinical Practice Guideline6 instructs providers to offer
active therapy only to smokers who are Bwilling^ to quit
in the next 30 days. The guideline recommends that
smokers who are not ready to quit receive brief motiva-
tional interventions (e.g., motivational interviewing) to
enhance readiness to quit.
The theoretical justification for evaluating smokers’
readiness to quit prior to offering therapy is rooted in
the transtheoretical model (TTM).7 This model describes
progression through five stages of change (SOC)
(precontemplation, contemplation, and preparation for
current smokers; action and maintenance for those who
have quit) that correlate with ten processes of behavior
change. Hundreds of published validation, population,
and intervention studies have evaluated the TTM in
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the context of tobacco use.8,9 According to the TTM,
Baction-oriented^ interventions such as cessation pharma-
cotherapy are most effective in the advanced stages.10–12
Unfortunately, 80 % of U.S. smokers have historically
fallen into the precontemplation and contemplation
stages.13,14 As motivated smokers have quit in response
to public health campaigns and policy initiatives,15 the
proportion of smokers in preparation has dropped even
further, with levels now at only 9–12 %.16,17 Efforts to
help early-stage smokers transition to higher stages through
motivational interviewing have produced mixed results.18
As the percentage of smokers in preparation shrinks, the
practice of offering active therapy only to those preparing
to quit will have diminishing returns.
While the TTM has served as a useful framework for
understanding behavior change, it has limitations as the
basis for clinical practice guidelines. The TTM system-
atically underestimates smokers’ motivation to quit,19–21
as many, if not most, precontemplators and contempla-
tors both want to and try to quit.22 In fact, several
interventions have documented successful abstinence
among precontemplators and contemplators.23–25 These
results substantiate critiques of the construct validi-
ty21,26–28 and inherent instability of the TTM stages.21,29
Interventions that proactively offer evidence-based
smoking cessation therapies to all smokers, regardless
of SOC, may provide an opportunity to reduce the
prevalence of smoking.30
The Veterans Victory Over Tobacco Study randomized
smokers to usual care or to a proactive, population-
based tobacco cessation intervention that offered tele-
phone or in-person counseling, as well as access to
cessation medications, to smokers regardless of SOC.
The primary results revealed a statistically significant
higher population-level 6-month prolonged smoking ab-
stinence rate at 1 year for proactive care (13.5 %)
compared with usual care (10.9 %, p = 0.02).31 In this
secondary analysis, we evaluate the effectiveness of
proactive care among smokers at different baseline
SOC. Our primary question is whether a proactive
outreach intervention will increase prolonged abstinence
even among those who say they are not ready to quit.
Secondary outcomes include the uptake of cessation
therapies and quit attempts by smokers at each SOC.
METHODS
Study Design and Participants. The Veterans Victory Over
Tobacco Study was a pragmatic randomized controlled
trial, and was approved by the institutional review
boards of all participating sites. Current smokers (aged
18 to 80 years) were identified using the US
Department of Veterans Affairs (VA) electronic medical
record health factor data set. Participants were recruited
from October 2009 to September 2010 from four VA
medical centers (New York, NY; Jackson, MS; Tampa,
FL: Minneapolis, MN), and follow-up was completed in
November 2011. Additional details of the trial design
and methods were described previously.31,32
Treatment. The proactive care intervention comprised
proactive outreach (mailed materials followed by
telephone outreach) combined with an offer of
telephone smoking cessation counseling or referral to
in-person counseling. Telephone care included a combi-
nation of proactive calls from trained counselors at the
Minneapolis VA and facilitated access to smoking ces-
sation pharmacotherapy through the participant’s VA
provider. The usual care group did not receive proactive
outreach but did have access to smoking cessation ser-
vices through their local VA and their state telephone
quitline.
Data Collection. VA administrative and health care utilization
data were obtained from the VA National Patient Care
Database. Survey data were collected at baseline and 1-year
follow-up.
Measures.Nicotine dependence was evaluated at baseline
and follow-up using time to first morning cigarette and
number of cigarettes per day.33 SOC was assessed at
baseline and follow-up with the ten-point Readiness to
Quit Ladder (RQL).34 Ladder responses 1 through 10
were categorized into low (1–4), medium (5–6), and
high (7–10) levels of readiness that approximate and
are referenced hereafter as precontemplation, contempla-
tion, and preparation (adapted from Abrams et al.34).
The primary outcome was self-reported 6-month
prolonged abstinence at 1-year follow-up, and was
assessed among all participants, regardless of treatment
utilization. Secondary outcomes included uptake of
smoking cessation therapies and quit attempts measured
at baseline and follow-up. The use of behavioral
counseling (telephone or in-person) and/or smoking ces-
sation medications from any source (including
bupropion, varenicline, and nicotine replacement therapy
[NRT]) was self-reported. Medications were also
assessed using administrative prescription data. Quit at-
tempts were assessed with the question, BDuring the
past 12 months, how many times have you quit smoking
intentionally for 24 hours or longer?^
Analysis. We used stratified random sampling (by site) to
select the study sample and a completely randomized block
design to assign participants to the intervention or usual care.
Accordingly, our estimations, testing, and modeling
procedures are stratified analyses. To compare baseline
879Danan et al.: Does Motivation Matter? Proactive Outreach to SmokersJGIM
characteristics across the SOC, the weighted stratifiedWald χ2
was used for categorical variables and the weighted stratified
F-test was used for continuous variables. The weights were
inverses of the sampling proportions from each site. To
account for possible intra-block correlations, logistic regres-
sion mixed modeling was used to test the effect of SOC on the
primary outcome, 6-month prolonged abstinence. All models
included the intervention and blocking factor (site). We tested
the interaction between SOC and treatment armwith respect to
the primary outcome. Randomization was not stratified by
SOC, which allowed for potentially imbalanced covariates
(both measured and unmeasured) between the two treatment
arms within each SOC to occur by chance, and this may have
created a biased interaction term. To control for between-
group imbalances, we have presented a stratified analysis,
comparing the treatment effect within each SOC separately.
Imbalanced characteristics at the 0.05 significance level were
included in the models as adjusting covariates.
To handle non-response, we hypothesized that this
might depend on the unobserved smoking status of the
subject; that is, we assumed a not-missing-at-random
(NMAR) mechanism. We modeled the joint distribution
of abstinence status and response status for the logistic
regressions using an expectation–maximization algorithm
to find maximum likelihood estimators, as described by
Ibrahim and colleagues.35,36 This likelihood-based NMAR
method creates two data sets, one that assumes all non-
responders are smokers, and another that assumes they are
all quitters. Then, through a series of iterative weightings,
it produces maximum likelihood estimates. The data anal-
ysis for this paper including the macro for likelihood-
based NMAR modeling was generated using SAS/STAT
software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the 5123 eligible, randomized participants, 3006 provided
complete baseline survey data, including the RQL, and thus
constitute the sample for this secondary analysis (58.5 %
[1473/2519] of those randomized to the proactive care inter-
vention and 58.9 % [1533/2604] of those in usual care). At
baseline, 781 smokers were in precontemplation (26.0 %),
1148 were in contemplation (38.2 %), and 1077 were in
preparation (35.8 %) (Table 1).
Within precontemplation and contemplation, observed
baseline characteristics were balanced across treatment groups
(Tables 3 and 4, available online). However, for the
preparation group, male gender and level of agreement with
the statement BPeople important to me want me to quit
smoking^ were not balanced across treatment groups
(Table 5, available online). These imbalanced variables were
included in the complete case and the NMAR models as
adjusting covariates.
Primary Outcome: 6-Month Prolonged Absti-
nence (Table 2)
Six-month prolonged abstinence at 1 year varied by
baseline SOC (5.4 % for precontemplators, 8.6 % for
contemplators, and 17.1 % for preparers [p < 0.001]).
The overall interaction between SOC and treatment
arm was not statistically significant (p = 0.30). Among
smokers in preparation, those randomized to the proac-
tive intervention were more likely to quit than those in
usual care (21.1 % vs 13.1 %, respectively, p=0.003).
Logistic regression mixed modeling analysis, taking into
account treatment arm and facility as well as the
adjusting covariates described above, found a significant
effect of proactive care compared with usual care among
preparers (OR, 1.8 [95 % CI, 1.2–2.6]). Similarly,
smokers in contemplation who were randomized to the
proactive intervention were more likely to quit than
those in usual care (11.0 % vs 6.5 %, p = 0.018; OR,
1.8, [95 % CI, 1.1–2.8]).). Smokers in precontemplation
quit at similar rates in the two treatment arms (5.3 % vs
5.6 %, p = 0.85; OR, 0.9, [95 % CI, 0.5–1.9]). Analyses
accounting for nonresponse using likelihood-based
NMAR models showed a similar effect of the proactive
care intervention on prolonged abstinence at each SOC
(Table 2). Of the 254 study participants who achieved 6-
month prolonged abstinence, 55.6 % began the study in
preparation, while 44.4 % were not ready to quit at
baseline (12.5 % began in precontemplation and
31.9 % in contemplation).
Secondary Outcomes
Uptake of Smoking Cessation Therapies (Fig. 1).
Smokers at all SOCwho were randomized to proactive care
engaged in telephone counseling at significantly higher rates
than usual-care smokers (7.4 vs. 0.6 % for precontemplation;
16.6 vs 2.7 % for contemplation; 18.8 vs. 3.1 % for prepara-
tion) and reported combined therapy with counseling and
cessation medication at significantly higher rates than usual
care smokers (6.0 vs. 1.5 % for precontemplation; 14.1 vs.
5.7 % for contemplation; 20.7 vs 8.4 % for preparation).
Smokers in all SOC who received proactive care were more
likely than usual care participants to be prescribed cessation
medications through the VA, though this difference reached
statistical significance only for contemplation and preparation
(20.2 vs. 16.1 % for precontemplation [NS]; 40.9 vs. 33.3 %
for contemplation; 44.9 vs. 37.4 % for preparation). Study
participants reported using in-person counseling or attending
VA smoking cessation clinics at low rates that were not sig-
nificantly different by study arm or by baseline SOC.
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Quit Attempts. Baseline SOC predicted the likelihood of
making a quit attempt during the study period. Overall,
31.3 % of precontemplators, 55.6 % of contemplators, and
73.5 % of preparers reported making at least one 24-hour quit
attempt during the study follow-up period. There was no
significant difference in quit attempts between proactive and
usual care.
DISCUSSION
This proactive population-based smoking cessation inter-
vention included smokers at all stages of change (SOC),
and increased long-term prolonged abstinence for
smokers in both preparation and contemplation. Smokers
in precontemplation did not quit at higher rates in re-
sponse to proactive outreach, but they were more likely
to try evidence-based cessation interventions, including
telephone counseling and combined counseling and
pharmacotherapy. Proactively offering evidence-based
cessation therapies to all smokers led to increased ther-
apeutic engagement and higher long-term population-
level quit rates.
Our assessment of an overall interaction between SOC
and treatment group revealed no statistically significant
difference among SOC subgroups with respect to the
Table 1 Participant Characteristics by Baseline Stage of Change
Total, n Precontemplation,
n (%)*or mean (SD)
Contemplation,
n (%) or mean (SD)
Preparation,
n (%) or mean (SD)
p value
All participants 3006 781 1148 1077 –
Treatment group
Usual care 1533 (51.3) 396 (50.6) 585 (50.7) 552 (52.5) 0.64
Proactive care 1473 (48.7) 385 (49.5) 563 (49.2) 525 (47.5)
Demographic characteristics:
Age (years) 57.7 (10.6) 59.4 (10.3) 57.0 (10.7) 57.3 (10.5) <0.001
Race
White 1852 (67.2) 543 (74.4) 737 (70.0) 572 (58.4) <0.001
Black 774 (22.2) 154 (16.4) 280 (20.2) 340 (29.0)
Hispanic 85 (4.5) 41 (4.2) 59 (3.6) 85 (5.8)
Other 95 (6.1) 43 (5.1) 72 (6.2) 80 (6.8)
Gender
Male 2838 (94.4) 741 (94.9) 1080 (94.2) 1017 (94.1) 0.71
Marital status
Married 1460 (50.0) 337 (44.8) 602 (53.6) 521 (50.0) 0.001
Socioeconomic status:
Income ($)
< 10,000 511 (17.0) 123 (16.1) 185 (16.0) 203 (18.9) 0.001
10,000–20,000 879 (30.8) 238 (32.8) 307 (28.1) 334 (32.4)
20,001–40,000 841 (30.5) 841 (29.7) 207 (30.4) 323 (31.3)
Q 40,001 593 (21.6) 155 (21.4) 266 (25.5) 172 (17.4)
Social and environmental pressures:
Home smoking rules
Not allowed anywhere 1116 (41.1) 237 (33.3) 406 (39.8) 473 (48.6) <0.001
Allowed some places/times 602 (20.7) 142 (19.2) 219 (20.0) 241 (22.3)
Allowed anywhere 1087 (38.2) 354 (47.5) 438 (40.2) 295 (28.7)
Friends who smoke
None 454 (16.2) 116 (15.8) 171 (16.2) 167 (16.5) 0.001
< half 809 (28.7) 185 (24.6) 296 (27.9) 328 (32.7)
About half 614 (22.2) 163 (22.3) 238 (22.7) 213 (21.7)
> half 530 (19.4) 134 (18.8) 217 (21.0) 179 (18.0)
All 384 (13.6) 130 (18.6) 135 (12.2) 119 (11.2)
People important to me want me to quit smoking
Strongly disagree to neutral 580 (21.6) 267 (37.8) 188 (17.9) 125 (13.2) <0.001
Somewhat agree 628 (22.8) 196 (26.7) 234 (23.1) 198 (19.3)
Strongly agree 1569 (55.6) 263 (35.5) 635 (59.0) 671 (67.5)
Smoking behaviors:
Cigarettes per day
e 10 1018 (31.3) 211 (24.7) 290 (22.3) 517 (46.7) <0.001
11–20 1286 (45.0) 341 (46.3) 547 (49.5) 398 (38.9)
Q 21 652 (23.7) 213 (29.0) 301 (28.3) 138 (14.4)
Time to first cigarette, min
Q 31 809 (25.8) 185 (23.2) 249 (20.7) 375 (33.6) <0.001
6–30 1535 (52.6) 402 (52.2) 615 (55.1) 518 (50.1)
< 5 638 (21.6) 188 (24.6) 278 (24.2) 172 (16.3)
Quit in past 12 months
Yes 1673 (54.4) 181 (22.4) 626 (53.2) 866 (80.6) <0.001
Longest quit length
Never quit 255 (8.3) 128 (16.3) 72 (6.1) 55 (4.7) <0.001
< 1 month 824 (27.1) 230 (29.5) 334 (27.9) 260 (24.2)
1–6 months 809 (27.2) 187 (24.4) 309 (27.5) 313 (28.9)
> 6 months 1092 (37.5) 225 (29.8) 426 (38.5) 441 (42.2)
* Observed count (weighted column proportion)
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intervention. Interaction tests are often underpowered
and may be biased when the study is not designed to
detect these subgroup effects and randomization is not
stratified by subgroup. Thus, we presented additional
stratified analyses demonstrating the effect of proactive
outreach on smokers at each baseline stage. Among
highly motivated smokers (preparation), 73.5 % of
whom made at least one quit attempt during follow-up,
proactive outreach increased the likelihood of quitting
successfully by 50 % (21.1 % vs 13.1 %). Though
proactive outreach targets less motivated smokers,37 we
found that even highly motivated smokers benefited
from proactive outreach through increased uptake of
cessation therapies.
Proactive outreach to contemplators appeared to in-
crease cessation by helping smokers overcome high
nicotine dependence through the use of evidence-based
therapies. Contemplators had attempted to quit in the
past at rates similar to preparers, but had much higher
levels of nicotine dependence (Table 1). A history of
past quit attempts is a predictor of future attempts, but
nicotine dependence levels predict the success of those
attempts.38,39 Increased therapeutic engagement by con-
templators resulted in more successful quit attempts. Our
finding that treatment engagement was associated with
cessation (OR 1.55 [95 % CI 1.06–2.28] for use of
combined therapy) supports this proposed mechanism.
Although proactive outreach increased treatment en-
gagement among precontemplators, we did not observe a
difference in smoking cessation rates. It may be that
proactive outreach that offers standard cessation thera-
pies is ineffective for precontemplators, who face greater
barriers to quitting40 and may require tailored or high-
intensity therapy.23 Alternatively, our analysis may have
been underpowered to show a difference in cessation
among precontemplators, given the smaller size of the
subgroup and lower baseline quit rates. Further research
is needed for a definitive answer to this question. We
found no evidence that the proactive intervention in-
creased unsuccessful quit attempts among precon
templators (31.4 % of precontemplators in usual care
and 31.3 % in proactive care made at least one quit
attempt during follow-up [p=0.98]), and thus have no
reason to believe that proactive care poses harm to
precontemplators.
Our results replicate and extend prior research that has
evaluated population-based smoking cessation interven-
tions for smokers at all SOC. Since 1995, when Curry
and colleagues first demonstrated the potential effective-
ness of telephone-based interventions with non-volunteer
smokers at all SOC,25 dozens of telephone-based trials in
various populations have supported this proactive ap-
proach. However, most have measured only point-
prevalent abstinence and/or found short-term (6–9-month
follow-up) effects.37,41,42 In contrast, our proactive care
intervention achieved prolonged abstinence at long-term
(12-month) follow-up among both preparers and contem-
plators. One reason for this robust effect may be that we
combined population-based outreach (using electronic
health technology to identify current smokers and to offer
telephone-based care) with individual care management
Table 2 Primary Outcome: 6-Month Prolonged Abstinence by
Baseline Stage of Change and Treatment Arm
Baseline stage of
change










































* Observed count (weighted column proportion)
† Usual care is the reference group
‡ Among follow-up survey respondents
§ Likelihood-based NMAR (not-missing-at-random) model accounting
for non-response
Figure 1 Engagement with smoking cessation therapies by baseline
stage of change and treatment arm. PC=precontemplation,
C = contemplation, P = preparation, ns = not significant,
TC= telephone counseling, C&Rx= counseling & medication, VA
Rx=VA-prescribed medication. * 95 % confidence interval for odds
ratio does not contain 1.
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(linking care to VA providers to facilitate pharmacothera-
py). Smokers in proactive care were much more likely to
use combined counseling and pharmacotherapy (Fig. 1),
which has been shown to be highly effective.4,6
While earlier telephone counseling studies have included
smokers at all SOC, those studies did not provide informa-
tion as to whether smokers at lower SOC benefitted from
the interventions or merely diluted the population-level
treatment effect. In 2015, Haas and colleagues43 addressed
this deficiency, reporting that their telephone-based
intervention using interactive voice response increased
abstinence both among those planning to quit within the
next 30 days and among those with no plans to quit. Our
report provides additional information on the magnitude of
the treatment effect on less motivated smokers and divides
less motivated smokers into subgroups of precontemplators
and contemplators.
Interest in treating smokers at all SOC has grown over
the past decade. In 2005, Pisinger and colleagues first
reported the success of the Inter99 trial, which found that
a high-intensity intervention could engage less motivated
smokers and increase rates of abstinence.23,44 Several
editorials, citing the success of Inter99, have questioned
current guideline recommendations to assess motivation
to quit prior to offering cessation therapy.26,45 Aveyard
and colleagues conducted a systematic review and
meta-analysis of brief physician interventions among
smokers at all motivation levels and concluded that
combining physician advice to quit with the offer of
cessation support motivated an additional 40–60 % of
smokers to attempt to quit, compared with advice
alone.30 The authors suggested that offering assistance
in quitting to smokers at all SOC may be effective
because the offer itself increases confidence in success.
To explain why less motivated smokers often respond to
offers of cessation therapy, others have advanced an
alternative theory of smoking cessation based in
Bcatastrophe theory,^ which posits that motivational
tension fluctuates, and small triggers can induce
apparently spontaneous quit attempts.46,47
Carpenter and colleagues subsequently reported that among
unmotivated smokers, NRT sampling was more successful for
inducing quit attempts and short-term cessation than practice
quit attempts alone.48 Two additional small studies compared
the offer of NRT to usual care and found promising short-term
results regardless of motivation.49,50 After more than a decade
of small studies, meta-analyses, and editorials, we now report
on the largest low-intensity, pragmatic, proactive care inter-
vention with long-term outcomes among smokers who were
not planning to quit at baseline.
Limitations include a study population of mostly older male
US veteran smokers, which may limit generalizability to other
populations of smokers. Our study, a non-pre-specified sub-
group analysis, is restricted to those participants who complet-
ed the baseline survey questions that established SOC, and
thus this sample may be more engaged than the overall pop-
ulation. Follow-up data availability is limited to an even
smaller group. We address the potential for response bias in
follow-up data by including a likelihood-based NMARmodel
analysis. In the primary analysis,31 we also addressed possible
differential non-response between treatment groups, and
found that taking into account non-response bias did not
substantially alter the results. Additional limitations result
from inconsistencies in operationalizing the TTM across the
literature, making it difficult to compare our SOCwith those in
other studies.9
This large, pragmatic randomized trial of a telephone-based
intervention demonstrated increased uptake of smoking
cessation therapies and prolonged abstinence at 1 year both
for smokers who were already planning to quit and for those
who were not. Similar to the results of prior studies,23,25 we
found that among participants who quit successfully, nearly
half began the study stating that they were not ready to quit.
Restricting therapy to only those in the preparation stage
would exclude 64 % of the smokers in our sample, and 44 %
of those who quit. Our results add to the growing body of
evidence that smoking cessation therapy should be proactively
offered to all smokers, regardless of stated plans to quit.
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Table 3 Baseline Participant Characteristics by Treatment Group Within Precontemplation
Total, n Proactive care,
n (%)* or mean (SD)
Usual care,
n (%) or mean (SD)
p value
All participants 781 385 396 –
Demographic characteristics:
Age (years) 59.4 (10.3) 58.8 (10.6) 59.9 (10.0) 0.06
Race
White 543 (74.4) 256 (71.7) 287 (77.0) 0.25
Black 154 (16.4) 84 (17.6) 70 (15.2)
Hispanic 41 (4.2) 20 (4.3) 21 (4.0)
Other 43 (5.1) 25 (6.2) 18 (3.8)
Gender
Male 741 (94.9) 366 (95.2) 375 (94.6) 0.71
Marital status
Married 337 (44.8) 181 (48.3) 156 (41.3) 0.06
Socioeconomic status:
Income, ($)
< 10,000 123 (16.1) 64 (17.3) 59 (15.01) 0.43
10,000–20,000 238 (32.8) 103 (29.8) 135 (35.6)
20,001–40,000 841 (29.7) 107 (31.3) 100 (28.2)
≥ 40,001 155 (21.4) 76 (21.7) 79 (21.2)
Social and environmental pressures:
Home smoking rules
Not allowed anywhere 237 (33.3) 121 (35.1) 116 (31.5) 0.20
Allowed some places/times 142 (19.2) 73 (20.8) 69 (17.7)
Allowed anywhere 354 (47.5) 161 (44.1) 193 (50.8)
Friends who smoke
None 116 (15.8) 51 (14.4) 65 (17.0) 0.75
< half 185 (24.6) 91 (24.6) 94 (24.6)
About half 163 (22.3) 79 (21.4) 84 (23.1)
> half 134 (18.8) 70 (20.4) 64 (17.2)
All 130 (18.6) 64 (19.2) 66 (18.1)
People important to me want me to quit smoking
Strongly disagree to neutral 267 (37.8) 123 (36.4) 144 (39.1) 0.19
Somewhat agree 196 (26.7) 109 (29.9) 87 (23.7)
Strongly agree 263 (35.5) 118 (33.7) 145 (37.2)
Smoking behaviors:
Cigarettes per day
≤ 10 211 (24.7) 111 (26.4) 100 (23.1) 0.35
11–20 341 (46.3) 157 (43.7) 184 (48.9)
≥ 21 213 (29.0) 107 (30.0) 106 (28.0)
Time to first cigarette (min)
≥ 31 185 (23.2) 94 (23.4) 91 (23.0) 0.95
6–30 402 (52.2) 196 (51.6) 206 (52.7)
< 5 188 (24.6) 92 (25.0) 96 (24.3)
Quit in past 12 months
Yes 181 (22.4) 91 (22.8) 90 (22.1) 0.80
Longest quit length
Never quit 128 (16.3) 65 (16.8) 63 (15.8) 0.25
< 1 month 230 (29.5) 126 (32.6) 104 (26.4)
1–6 months 187 (24.4) 83 (22.5) 104 (26.3)
> 6 months 225 (29.8) 107 (28.1) 118 (31.5)
* Observed count (weighted column proportion)
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Table 4 Baseline Participant Characteristics by Treatment Group Within Contemplation
Total, n Proactive care,
n (%)* or mean (SD)
Usual care,
n (%) or mean (SD)
p value
All participants 1148 563 585 –
Demographic characteristics:
Age (years) 57.0 (10.7) 56.6 (10.9) 57.2 (10.4) 0.32
Race
White 737 (70.0) 358 (69.5) 287 (70.5) 0.18
Black 280 (20.2) 150 (22.2) 130 (18.3)
Hispanic 59 (3.6) 26 (3.0) 33 (4.1)
Other 72 (6.2) 29 (5.3) 43 (7.1)
Gender
Male 1080 (94.2) 530 (94.3) 550 (94.1) 0.88
Marital status
Married 602 (53.6) 292 (52.8) 310 (54.4) 0.60
Socioeconomic status:
Income ($)
< 10,000 185 (16.0) 85 (15.1) 100 (16.8) 0.81
10,000–20,000 307 (28.1) 154 (28.2) 153 (28.0)
20,001–40,000 207 (30.4) 164 (31.6) 159 (29.3)
≥ 40,001 266 (25.5) 132 (25.2) 134 (25.9)
Social and environmental pressures:
Home smoking rules
Not allowed anywhere 406 (39.8) 209 (41.4) 197 (38.3) 0.45
Allowed some places/times 219 (20.0) 97 (18.5) 122 (21.4)
Allowed anywhere 438 (40.2) 214 (40.1) 224 (40.3)
Friends who smoke
None 171 (16.2) 88 (17.1) 83 (15.2) 0.26
< half 296 (27.9) 132 (25.1) 164 (30.5)
About half 238 (22.7) 117 (22.4) 121 (23.1)
> half 217 (21.0) 109 (21.7) 108 (20.4)
All 135 (12.2) 71 (13.7) 64 (10.8)
People important to me want me to quit smoking
Strongly disagree to neutral 188 (17.9) 95 (18.3) 93 (17.5) 0.30
Somewhat agree 234 (23.1) 102 (21.0) 132 (25.2)
Strongly agree 635 (59.0) 321 (60.7) 314 (57.4)
Smoking behaviors:
Cigarettes per day
≤ 10 290 (22.3) 140 (22.1) 150 (22.4) 0.94
11–20 547 (49.5) 274 (50.0) 273 (48.9)
≥ 21 301 (28.3) 143 (27.9) 158 (28.6)
Time to first cigarette (min)
≥ 31 249 (20.7) 116 (20.0) 133 (21.4) 0.41
6–30 615 (55.1) 298 (54.1) 317 (56.1)
< 5 278 (24.2) 146 (26.0) 132 (22.5)
Quit in past 12 months
Yes 626 (53.2) 307 (54.4) 319 (52.1) 0.46
Longest quit length
Never quit 72 (6.1) 38 (6.6) 34 (5.5) 0.70
< 1 month 334 (27.9) 172 (29.1) 162 (26.8)
1–6 months 309 (27.5) 149 (27.1) 160 (27.9)
> 6 months 426 (38.5) 201 (37.3) 225 (39.7)
* Observed count (weighted column proportion)
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Table 5 Baseline Participant Characteristics by Treatment Group Within Preparation
Total, n Proactive care,
n (%)* or mean (SD)
Usual care,
n (%) or mean (SD)
p value
All participants 1077 525 552 –
Demographic characteristics:
Age (years) 57.4 (10.5) 57.2 (10.3) 57.6 (10.8) 0.47
Race
White 572 (58.4) 260 (55.0) 312 (61.6) 0.20
Black 340 (29.0) 178 (31.2) 162 (27.1)
Hispanic 85 (5.8) 43 (6.2) 42 (5.4)
Other 80 (6.8) 44 (7.7) 36 (5.9)
Gender
Male 1017 (94.1) 504 (95.7) 513 (92.6) 0.045
Marital status
Married 521 (50.0) 250 (50.0) 271 (50.1) 0.98
Socioeconomic status:
Income ($)
< 10,000 203 (18.9) 98 (19.0) 105 (18.9) 0.91
10,000–20,000 334 (32.4) 170 (33.4) 164 (31.6)
20,001–40,000 311 (31.3) 146 (31.2) 165 (31.4)
≥ 40,001 172 (17.4) 81 (16.5) 91 (18.1)
Social and environmental pressures:
Home smoking rules
Not allowed anywhere 473 (48.6) 227 (48.3) 246 (48.9) 0.58
Allowed some places/times 241 (22.3) 113 (21.7) 128 (23.7)
Allowed anywhere 295 (28.7) 151 (30.1) 144 (27.4)
Friends who smoke
None 167 (16.5) 85 (16.7) 82 (16.3) 0.96
< half 328 (32.7) 149 (31.5) 179 (33.7)
About half 213 (21.7) 104 (22.0) 109 (21.5)
> half 179 (18.0) 92 (18.8) 87 (17.3)
All 119 (11.2) 59 (11.1) 60 (11.2)
People important to me want me to quit smoking
Strongly disagree to neutral 125 (13.2) 47 (10.1) 78 (16.0) 0.031
Somewhat agree 198 (19.3) 99 (19.7) 99 (18.9)
Strongly agree 671 (67.5) 332 (70.3) 339 (65.1)
Smoking behaviors:
Cigarettes per day
≤ 10 517 (46.7) 244 (45.3) 273 (48.0) 0.67
11–20 398 (38.9) 201 (40.4) 197 (37.7)
≥ 21 138 (14.4) 67 (14.4) 71 (14.4)
Time to first cigarette, min
≥ 31 375 (33.6) 172 (32.5) 203 (34.5) 0.75
6–30 518 (50.1) 259 (50.5) 259 (49.8)
< 5 172 (16.3) 88 (17.0) 84 (15.7)
Quit in past 12 months
Yes 866 (80.6) 414 (80.0) 452 (81.1) 0.66
Longest quit length
Never quit 55 (4.7) 30 (5.5) 25 (4.1) 0.11
< 1 month 260 (24.2) 140 (26.4) 120 (22.2)
1–6 months 313 (28.9) 155 (29.8) 158 (28.2)
> 6 months 441 (42.2) 194 (38.4) 247 (45.6)
* Observed count (weighted column proportion)
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